Group B Streptococcus Infection Treatment Market Report 2026

The group b streptococcus infection treatment market size has grown strongly in recent years. It will grow from $1.26 billion in 2025 to $1.36 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing awareness of neonatal infections, expansion of prenatal care programs, widespread use of beta-lactam antibiotics, growth in hospital-based screening protocols, availability of microbiological testing services.

The group b streptococcus infection treatment market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing development of gbs vaccines, rising adoption of point-of-care diagnostics, growing focus on antimicrobial resistance management, expansion of molecular testing infrastructure, increasing emphasis on preventive maternal healthcare. Major trends in the forecast period include increasing adoption of rapid molecular diagnostic testing, rising focus on prenatal gbs screening programs, growing use of antibiotic stewardship protocols, expansion of pipeline therapies for gbs prevention, enhanced monitoring of maternal and neonatal outcomes.

The rising healthcare expenditure is expected to propel the growth of the group B streptococcus infection treatment market going forward. Healthcare expenditure refers to the total financial resources allocated to medical services, preventive care, medications, infrastructure, and related health activities aimed at maintaining or improving population health. Healthcare expenditure is increasing due to the growing prevalence of chronic and infectious diseases, which fuels demand for long-term care, advanced therapies, and continuous medical management. Rising healthcare expenditure supports group B Streptococcus infection treatment by enabling greater investment in prenatal screening, clinical infrastructure, and vaccine research, thereby improving early detection, prevention, and effective management of GBS infections in mothers and newborns. For instance, in April 2025, according to the Office for National Statistics, a UK-based government organization, overall healthcare spending increased by 6.5% from 2023 to 2024, up from a 6.3% growth recorded in 2023. Therefore, the rising healthcare expenditure is driving the growth of the group B streptococcus infection treatment market.

Companies operating in the group B streptococcus infection treatment market are focusing on developing innovative products, such as polysaccharide conjugate vaccines, to reduce asymptomatic bacterial carriage. Polysaccharide conjugate vaccines are immunizations in which bacterial surface sugars are chemically linked to a carrier protein to enhance immune recognition and generate a strong, long-lasting protective response, especially in infants and young children. For example, in September 2023, Omniose, a US-based biotechnology company, announced a grant award of up to $3 million from the National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health to support the development of a Group B Streptococcus (GBS) vaccine. The vaccine’s unique feature lies in its aim to achieve high efficacy through a highly simplified manufacturing approach. Omniose’s platform leverages synthetic biology and a one-step enzymatic process within a single re-engineered E. coli cell to produce GBS polysaccharide conjugate vaccines, eliminating conventional chemical conjugation steps. This process preserves 100% of sialic acid residues on each capsular polysaccharide, a factor shown to be critical for inducing strong functional antibody responses against specific GBS serotypes.

In September 2024, MinervaX ApS, a Denmark-based biotechnology company developing a novel prophylactic vaccine against Group B Streptococcus (GBS), partnered with Wacker Biotech B.V. to scale up the manufacturing of active protein ingredients for MinervaX’s GBS vaccine. Through this collaboration, MinervaX and Wacker Biotech aim to ensure robust late-stage clinical and commercial supply, enabling maternal vaccination to prevent adverse pregnancy outcomes and life-threatening infections in infants, as well as vaccination of older or at-risk adults. Wacker Biotech B.V. is a Germany-based company specializing in E. coli processes, technology transfer, process validation, and process characterization to support stable, high-quality vaccine production for global patient populations.

Major companies operating in the group b streptococcus infection treatment market are Merck & Co. Inc., Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Biological E. Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Vaxcyte Inc., Bharat Biotech International Limited, Clover Biopharmaceuticals Ltd., Biovac Institute (Pty) Ltd., Inventprise Inc., BioNet Asia Co. Ltd., GeneOne Life Science Inc., Alopexx Enterprises LLC, Wellstat Vaccines LLC, MinervaX ApS, and ShanghAI Zerun Biotechnology Co. Ltd.

Tariffs are impacting the group B streptococcus infection treatment market by increasing costs of imported diagnostic kits, molecular testing reagents, pharmaceutical ingredients, and medical laboratory equipment. Hospitals and diagnostic laboratories in North America and Europe are most affected due to dependence on imported reagents and testing platforms, while Asia-Pacific faces higher costs in manufacturing and distribution of diagnostics. These tariffs are increasing treatment and screening costs and affecting procurement budgets. However, they are also encouraging domestic production of diagnostic kits, localized pharmaceutical manufacturing, and investment in regional healthcare supply chains to improve long-term availability.

The group b streptococcus infection treatment market research report is one of a series of new reports that provides group b streptococcus infection treatment market statistics, including group b streptococcus infection treatment industry global market size, regional shares, competitors with a group b streptococcus infection treatment market share, detailed group b streptococcus infection treatment market segments, market trends and opportunities, and any further data you may need to thrive in the group b streptococcus infection treatment industry. This group b streptococcus infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Group B streptococcus infection treatment refers to the medical management of infections caused by Streptococcus agalactiae, affecting newborns, pregnant women, and immunocompromised adults. Treatment generally involves antibiotics to reduce bacterial load and prevent complications. Its main goal is to eliminate GBS bacteria, prevent adverse outcomes, and lower transmission risk, particularly from mother to infant.

The principal treatment types for Group B Streptococcus infection include antibiotic therapy, intravenous immunoglobulin, and experimental therapies. Antibiotic therapy involves using medications to eliminate or control bacterial infections caused by Group B Streptococcus. These treatments fall under drug classes such as beta-lactam antibiotics, clindamycin and alternatives, and pipeline therapies. Routes of administration include oral, intravenous, and topical applications. Patient types include newborns, pregnant women, immunocompromised individuals, and the elderly, with end users being hospitals, clinics, research institutions, and home care providers.

The group B streptococcus infection treatment market consists of revenues earned by entities by providing services such as prenatal screening and diagnostic testing, microbiological culture and molecular testing, clinical consultations for infection management, and antibiotic administration and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The group B streptococcus infection treatment market also includes sales of intrapartum prophylactic formulations, rapid diagnostic kits, molecular testing assays, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.